Candelaria Gomez-Manzano

Professor, tenure

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Candelaria Gomez-Manzano is a tenure Professor at The University of Texas MD Anderson Cancer Center in the United States. Her research focuses on immunotherapy and oncolytic virotherapies, particularly their application in treating brain tumors and enhancing antitumor immunity. Recent articles authored by Professor Gomez-Manzano explore the neurotoxicity of immunotherapy in pediatric patients, as well as innovative strategies for using oncolytic adenoviruses in cancer treatment.

Articles (14)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (6)

Hong Jiang

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

marisol gonzalez-huarriz

Clinica Universidad de Navarra

SPAIN

View details

Dalis Collins

Associate Professor and Director of the ABSL-3 Facility

University of Michigan

UNITED STATES

View details

Juan Fueyo

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Melissa Chen

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jiasen He

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Candelaria Gomez-Manzano

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Immunotherapy-related neurotoxicity in the central nervous system of children with cancer

Oncolytic adenoviruses and immunopeptidomics: a convenient marriage

Targeting Innate Immunity in Glioma Therapy

Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas

Adjuvant Therapy with Oncolytic Adenovirus Delta-24-RGDOX After Intratumoral Adoptive T-cell Therapy Promotes Antigen Spread to Sustain Systemic Antitumor Immunity

Remission of liquid tumors and SARS-CoV-2 infection: A literature review

Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma

Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas

Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory

An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus

CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy

Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET

Endovascular selective intra-arterial infusion of mesenchymal stem cells loaded with Delta-24 in a canine model

Collaborators (6)

Hong Jiang

marisol gonzalez-huarriz

Dalis Collins

Juan Fueyo

Melissa Chen

Jiasen He

Make your next move.